REGN Aug 2024 940.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 01:37PM EDT. Market open.
Loading interactive chart…
- GlobeNewswire
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Approval in patients with pJIA weighing 63kg or greater adds to Kevzara’s position in treating adult chronic inflammatory conditions of moderately to severely active rheumatoid arthritis and polymyalgia rheumatica TARRYTOWN, N.Y. and CAMBRIDGE, MA, June 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration has approved Kevzara® (sarilumab) for the treatment of patients weighing 63 kg or greater with activ
- Simply Wall St.
Is Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock's Recent Performance A Reflection Of Its Financial Health?
Regeneron Pharmaceuticals' (NASDAQ:REGN) stock up by 4.9% over the past month. Since the market usually pay for a...
- Zacks
Health Care Stocks Show Relative Strength as S&P 500 Stalls
Several stocks are breaking out and trading near all-time highs.
© 2024 Yahoo. All rights reserved.